<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905190</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-P8-689</org_study_id>
    <nct_id>NCT00905190</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Anti Nausea Medication With and Without Food</brief_title>
  <acronym>EUR-1025</acronym>
  <official_title>Single Dose Crossover Comparative Bioavailability Study To Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR1025) in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effect of food on a single dose of EUR-1025 when taken with a
      meal and taken on an empty stomach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the effect of food on the pharmacokinetics of a
      single 24 mg dose of EUR-1025 administered as a novel modified-release capsule formulation
      under fed and fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of food on the pharmacokinetics of a single 24 mg dose of ondansetron administered under fed and fasting conditions</measure>
    <time_frame>1 dose on two separate days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>24 mg one time</description>
    <arm_group_label>Fed</arm_group_label>
    <arm_group_label>Fasting</arm_group_label>
    <other_name>EUR-1025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers,

          -  Non- or ex-smokers,

          -  Of at least 21 years of age but not older than 55 years with a body mass index
             targeted to be at least 18.5 and less than 30 kg/m2,

          -  Healthy, normal lab values,

          -  Negative HIV, Hepatitis B &amp; C and a negative ethyl alcohol and drug screen,

          -  Normal 12 lead ECG, negative human chorionic gonadotropin (hCG) for females.

        Exclusion Criteria:

          -  No known hypersensitivity to Ondansetron or any related products,

          -  Presence of significant gastrointestinal, liver or kidney disease,or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects,

          -  History of significant gastrointestinal, liver or kidney disease,

          -  Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease,

          -  Suicidal tendency,

          -  History of or disposition to seizures, state of confusion, clinically relevant
             psychiatric disease,

          -  Presence of significant heart disease or disorder discovered on screening ECG,

          -  Females who are found to have a positive serum pregnancy test at screening or are
             nursing,

          -  Females of childbearing potential who refuse to use an acceptable contraceptive
             regimen from the screening visit and throughout the study,

          -  Maintenance therapy with any drug,

          -  Significant history of drug dependency or alcohol abuse (&gt; 2 units of alcohol per day,
             intake of excessive alcohol, acute or chronic),

          -  Any clinically significant illness in the previous 28 days before day 1 of the study,

          -  Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin,
             ciprofloxacin,fluconazole, ketoconazole,diltiazem and HIV antivirals) and strong
             inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids,
             phenytoin and rifampin), in the previous 28 days before day 1 of this study,

          -  Volunteers who took an Investigational Product (in another clinical trial) or donated
             50 ml or more of blood in the previous 28 days before day 1 of this study,

          -  Poor motivation, intellectual problems likely to limit the validity of consent to
             participate in the study or limit the ability to comply with the protocol requirements
             or inability to cooperate adequately,

          -  Inability to understand and to observe the instructions of the physician,

          -  Donation of 500 ml or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies) in the previous 56 days before day 1 of this study,

          -  Positive urine screening of drugs or abuse,

          -  Any history of tuberculosis and/or prophylaxis for tuberculosis,

          -  Positive results to HIV, HBsAg, or anti-HCV tests,

          -  No subjects will be allowed to enroll in this study more than once.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma INc.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

